Related Experiment Video
Updated: Apr 30, 2026
08:18
Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
Published on: September 8, 2021
2.4K
BRAFV600E-mutant melanoma presenting with cardiac involvement
Douglas B Johnson1, Jeffrey A Sosman
1From the Department of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, Tennessee.
Summary
Metastatic melanoma with BRAF mutations can affect the heart, posing treatment challenges. Management decisions for cardiac involvement balance targeted BRAF inhibitors against immune therapies.
Area of Science:
- Oncology
- Cardiology
- Dermatology
Background:
- Melanoma is an aggressive skin cancer with limited treatment options.
- Approximately 50% of melanomas harbor BRAF(V600) mutations.
- BRAF inhibitors and immune-based therapies are emerging treatments for BRAF-mutant melanoma.
Observation:
- This report details a 32-year-old male patient with metastatic BRAF(V600)-mutant melanoma.
- The patient presented with cardiac involvement, a clinically uncommon manifestation.
- This presentation poses challenging management decisions.
Findings:
- The optimal first-line therapy for BRAF-mutant melanoma is debated.
- Consensus suggests immune-based therapies for asymptomatic, low-volume disease.
- BRAF inhibitors are recommended for symptomatic or rapidly progressing disease.
Implications:
- Cardiac involvement in BRAF-mutant melanoma necessitates careful treatment strategy selection.
- Balancing targeted therapy and immunotherapy is crucial for effective patient management.
- Further research is needed to establish definitive treatment guidelines for this specific patient subgroup.
